

## References

1. Phillipson, J.D., and Anderson, L.A., Ethanopharmacology and western medicine, *Journal of Ethanopharmacology*; 4:973- 1010. (2000).
2. Midgley, J.M., Drug development; From sorcery to science, *Pharmaceutical Journal*; 241: 358- 365 (1988).
3. Hande, KR., Clinical applications of anticancer drugs targeted to topoisomerase II. *Biochim Biophys Acta*; 1400(1-3):173–184 (1998).
4. Kardner, S., Field guide to forest trees of Northern Thailand. Kobfai Publishing Project, Thailand; 217–218 (2000).
5. Keng, H., Order and families of malayan seed plants. Cathay Press, Hong Kong; 244–247 (1969).
6. Darwin, S.P., The Pacific species of *Ophiorrhiza* L. (Rubiaceae). *Lyonia*; v 1 (2) 47–102 (1976.).
7. Lo, H.-S., Taxonomic revision of the Chinese species of *Ophiorrhiza* (Rubiaceae). *Bulletin of Botanical Research North-Eastern Forestry Institute*; v10 (2): 1–82 (1990).
8. Deb, D.B., and Mondal, D.C., Taxonomic revision of the genus *Ophiorrhiza* L. (Rubiaceae) in Indian subcontinent. *Bulletin of the Botanical Survey India*; v 39 (1–4): 1–148 (1997, publ. 2001).
9. Puff, C., RUBIACEAE OF THAILAND: A pictorial guide to indigenous and cultivated genera. The Forest Herbarium Nation Park Wildlife and Plant Conservation Department Bangkok; (2005)
10. Hooker, JD., CB., KCSI., MD., FRS., Oxon, DCL., et al, The Flora of British India. *CAPRIFOLIACEAE TO APOCYNACEAE*. The authority of the secretary of state for India in Council; v 3: 77 -84 (1880).
11. Lu, F.Y., Kao, M.T., Huang, S.F., and Wang, J.C., Asclepiadaceae. In: Editorial Committee of the Flora of Taiwan. *Flora of Taiwan*. Department of Botany, National Taiwan University, Taipei; v 4 2<sup>nd</sup> ed: 308 (1998).

12. Kitajima, M., Masumoto, S., Takayama, H., Aimi, N., Isolation and Partial Synthesis of 3(R)- and 3(S)- Deoxypumiloside; Structural Revision of the Key Metabolite from the Camptothecin Producing Plant, *Ophiorrhiza pumila*. *J. Tetrahedron Letter*; 38(24): 4255-4258 (1997).
13. Aimi, N., Hoshino, H., Nishimura, M., Sakai, S., Haginiwa, J., Chaboside, first natural glycocamptothecin found from *Ophiorrhiza pumila*. *Tetrahedron Lett*; 31:5169–5172 (1990).
14. Yamazaki, Y., Urano, A., Sudo, H., Kitajima, M., Takayama, H., Yamazaki, M., Aimi, N., Laito, K., Metabolite profiling of alkaloids and strictosidine synthase activity in camptothecin producing plants. *J. Phytochemistry*; 62:461-470 (2003).
15. Aimi, N., Ueno, M., Hoshino, H., Sakai, S., Synthesis and absolute configuration of chaboside, first natural glucocamptothecin. *Tetrahedron Lett*; 33: 5403–5404(1992).
16. Aimi, N., Nishimura, M., Miwa, A., Hoshino, H., Sakai, S., Haginiwa, J., Pumiloside and deoxypumiloside; plausible intermediates of camptothecin biosynthesis. *Tetrahedron Lett* ; 30: 4991–4994 (1989).
17. Aimi, N., Tsuyuki, T., Murakami, H., Sakai, S., Haginiwa, J., Structure of ophiorhines A and B; novel type gluco indole alkaloids isolated from *Ophiorrhiza* spp. *Tetrahedron Lett*; 26:5299–5302 (1985)
18. Aimi, N., Murakami, H., Tsuyuki, T., Nishiyama, T., Sakai, S., Haginiwa, J., Hydrolytic degradation of b-carbolinetype monoterpenoid glucoindole alkaloids: a possible mechanism for harman formation in *Ophiorrhiza* and related rubiaceous plants. *Chem Pharm Bull*; 34:3064–3066 (1986).
19. Kitajima, M., Fujii, N., Yoshino, F., Sudo, H., Saito, K., Aimi, N., Takayama, H., Camptothecins and Two New Monoterpene Glucosides from *Ophiorrhiza liukiuensis*. *J. Chem. Pharm. Bull*; 53(10):1355-1358 (2005).
20. Pizzolato, J.F., Saltz, L.B., The camptothecin. *J. The Lancet*; 361: 2235-2242 (2003).
21. Kitajima, M., Yashida, S., Yamagata, K., Nakamura, M., Takayama, H., Saito, K., Seki, H., Aimi, N., Camptothecin-related alkaloids from hairy roots of *Ophiorrhiza pumila*. *J. Tetrahedron*; 58:9169-9178 (2002).

22. Kitajima, M., Chemical studies on monoterpenoid indole alkaloids from medicinal plant resources *Gelsemium* and *Ophiorrhiza*. *J. Nat Med*; 61: 14-23 (2007).
23. Wall, M E., Wani, M C., History and future prospects of camptothecin and taxol. In: Cordell G A (ed) *The alkaloids*, v 50. Academic, New York, and references cited therein : 509–535 (1998)
24. Kitajima, M., Kakamura, M., Takayama, H., Saito, K., Stockingt, J., Aimi, N., Constituents of Regenerated Plants of *Ophiorrhiza pumila*; Formation of a New Glycocamptothecin and Predominant Formation of (3*R*)-Deoxypumiloside over (3*S*)-Congener. *J.Tetrahedron Letters*; 38: 8997-9000 (1997).
25. Kitajima, M., Fujii, N., Yoshino, F., Sudo, H., Saito, K., Aimi, N., Takayama, H., Camptothecins and two new monoterpene glucosides from *Ophiorrhiza liukiensis*. *Chem Pharm Bull*; 53:1355–1358 (2005).
26. Arbain, D., Dachriyanus, Firmansyah, Sargent, M.V., Skelton, B.W., White, A.H., Unusual indole alkaloids from *Ophiorrhiza blumeana* Korth. *J.Chem.Soc.,Perkin Trans*; 1: 2537-254 (1998).
27. Arbain, D., Byrne, L.T., Dachriyanus, Evrayoza, N., Sargent, M.V., Bracteatine, a Quaternary Glucoalkaloid from *Ophiorrhiza bracteata* *Aust.J.Chem*; 50: 1111-1112 (1997).
28. Arbain, D., Byrne, L.T., Sachriyanus, Sargent, M.V., Isomalindine-16-carboxylate, a Zwitterionic Alkaloid from *Ophiorrhiza cf. communis*. *Aust. J. Chem*; 50: 1109-1110 (1997).
29. Fujii, T., Ohba, M., Seto, S., Quinolizidines. XXXIII. A Chiral Synthesis of (-)-Ophiorrhizine, a Pentacyclic Quaternary Indole Alkaloid from *Ophiorrhiza major* Ridl. *J. Chem. Pharm. Bull*; 23(1): 49-52 (1995).
30. Arbrain, D., Lajis, N.H., Putra, D.P., Sargent, M.V., Skelton, B.W., White, A.H., The Alkaloids of *Ophiorrhiza cf. ferruginea*. *Aust. J. Chem*; 46: 969-976 (1993).
31. Chan, H.H., Li, C-Y., Damu, A.G., Wu, T-S., Anthaquinones from *Ophiorrhiza hayatana* OHWI. *J. Chem. Pharm. Bull*; 53(10): 1232-1235 (2005).

32. Pettit, G.R., Biosynthetic products for cancer chemotherapy; Plenum Pub. Corp., New York. v 1: (1977).
33. Pettit, G.R., and Cragg, G.M., Biosynthetic products for cancer chemotherapy; Plenum Pub. Corp., New York. v 2:(1978).
34. Manosroi, A., and Manosroi, J., Natural Cytotoxic Substances and Immunoconjugates/ Immounotoxins in cancer therapy. Department of pharmaceutical Technology Faculty of Pharmacy, Chiang Mai University Chiang Mai. Thailand. (1992).
35. Sun Y., Huang, G.J, Wu, K.Y., eds., Medical treatment, Carcinoma of the esophagus and gastric cardia; Springer- Verlag, New York. 369-389: (1984).
36. Hoffmann, J., Iscador treatment of patients with liver metastases; Krebsgeschehen. v11 (6): 172-175 (1989).
37. Lerio, R., Iscador treatment of patents with inoperable colorectal tumors; Krebsgeschehen. v11 (6): 163-165 (1979).
38. Xu, B., Pharmacology of some natural products of China, *Trends Pharmacol. Sci*; 2 (10): 271- 272 (1978).
39. Redinbo, M.R., Styewart L., Kuhn P., Champoux J.J., and Hol W.G.J., Crystal structures of human topoisomerase I in covalent and monocovalent complexes with DNA. *Science*; v 279 (5356): 1504-1513 (March 1998).
40. Lorence, A., and Nessler, C.L., Molecule of Interest Camptothecin, over four decades of surprising findings. *Phytochemistry*; v 65 (20): 2735- 2749 (October 2004).
41. Lorence, A., Medina-Bolivar, F., and Nessler, C.L., Camptothecin and 10-hydroxycamptothecin from *Camptotheca acuminata* hairy roots. *Plant Cell Reports*; v22 (6): 437-441 (January 2004).
42. Pantazis, P., Han, Z., Chatterjee, D., and Wyche, James., Water-insoluble camptothecin analogues as potential antiviral drugs. *Journal of Biomedical Science*; v 6(1): 1-7 (January 1999).
43. Japan Pharmaceutical Information Center. Drugs in Japan, Ethical Drugs; Yakugyo Jiho Co. Tokyo. 169-270 (1995).

44. Becker, Y., and Olshevsky, U., Inhibition of herpes simplex virus replication by camptothecin. *Israel Journal of Medical Sciences*; v 9 (11-12): 1578-1581 (1973).
45. Giovanella, B.C., Stehlin, J.S., Wall, M.E., Wani, M.C., Nicholas, A.W., Liu, L.F., Silber, R., and Potmesil, M., DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. *Science*; v 246 (4933): 1046-1048 (November 1989).
46. Priel, E., Showalter, S.D., and Blair, D.G., Inhibition of human immunodeficiency virus (HIV-1) replication in vitro by noncytotoxic doses of camptothecin, a topoisomerase I inhibitor. *AIDS Research and Human Retroviruses*; v 7 (1): 65-72 (1991).
47. Takeuchi, S., Dobashi, K., Fukumoto, S., Tanaka, K., Suzuki, M., Terashima, Y., Hasumi, K., Akiya, K., Negishi, Y., Tamaya, T., A late phase II study of CPT-11 in gynecologic cancers. Research groups of CPT-11 in gynecologic cancers. *Japanese Journal of Cancer and Chemotherapy*; v 18 (10): 1681-1689 (August 1991).
48. Bodley, A.L., Cumming, J. N., and Shapiro, T.A., Effects of camptothecin, a topoisomerase I inhibitor, on *Plasmodium falciparum*. *Biochemical Pharmacology*; v 55 (5): 709-711 (March 1998).
49. Tafur, S., Nelson, J.D., Delong, D.C., and Svoboda, G.H., Antiviral components of *Ophiorrhiza mungos* isolation of camptothecin and 10-methoxycamptothecin. *Lloydia*; v 39 (4): 261- 262 (1976).
50. Saito, K., Sudo, H., Yamazaki, M., Kosekinakamura, M., Kitajima, M., Takayama, H., Aimi, N., Feasible production of camptothecin by hairy root cultures of *Ophiorrhiza pumila*. *Plant Cell Reports*; v 20 (3): 267-271 (March 2001).
51. Sudo, H., Yamakawa, T., Yamazaki, M., Aimi, N., and Saito, K., Bioreactor production of camptothecin by hairy root cultures of *Ophiorrhiza pumila*. *Biotechnology Letters*; v 24 (5): 359-363 (March 2002).
52. Watase, I., Sudo, H., Yamazaki, M., and Saito, K., Regeneration of transformed *Ophiorrhiza pumila* plants producing camptothecin. *Plant Biotechnology*; v 21 (5): 337-342 (2004).

53. Kirtikar, K.R., and Basu, B.D., *Indian Medicinal Plants Vol. II*. 2nd ed. M/S Bishen Singh Mahendrapal Singh, New Delhi, India; 1268-1269 (1975).
54. Roja, G., Comparative studies on the camptothecin content from *Nothapodytes foetida* and *Ophiorrhiza* Species. *J. Natural Product Research*; 20(1): 85-88 (2006).
55. Wall, ME., Wani, MC., Cook, CE., Palmer, KH., Plant antitumor agents, I: the isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from *Camptotheca acuminata*. *J. Am Chem Soc*; 88: 3888–90 (1966).
56. Hatefi, A., and Amsden, B., Camptothecin Delivery Methods. *J. Pharmaceutical Research*; 19(10): 1389-1399 (2002).
57. Moertel, CG., Schutt, AJ., Reitemeier, RJ., Hahn, RG., Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. *Cancer Chemother Rep*; 56: 95–101 (1972).
58. Hsiang, YH., Hertzberg, R., Hecht, S., Liu, LF., Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. *J. Biol Chem*; 260: 14873–78 (1985).
59. Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. *Cancer Res*; 48: 1722–26 (1988).
60. M.L. Rothenberg, Topoisomerase I inhibitors: Review and update. *Ann Oncol*; 8: 837-855 (1997).
61. Schneider E, Hsiang YH, Liu LF. DNA topoisomerases as anticancer drug targets. *Adv Pharmacol*; 21: 149–83 (1990).
62. Hsiang, YH., Lihou, MG., Liu, LF., Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. *Cancer Res*; 49: 5077–82 (1989).
63. Sane, AT., Bertrand, R., Caspase inhibition in camptothecin-treated U-937 cells is coupled with a shift from apoptosis to transient G1 arrest followed by necrotic cell death. *Cancer Res*; 59: 3565–69 (1999).
64. Li, LH., Fraser, TJ., Olin, EJ., Bhuyan, BK., Action of camptothecin on mammalian cells in culture. *Cancer Res*; 32: 2643–50 (1972).

65. Sugimoto, Y., Tsukahara, S., Oh-hara, T., Isoe, T., Tsuruo, T., Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. *Cancer Res*; 50: 6925–30 (1990).
66. Giovanella, BC., Stehlin, JS., Wall, ME., Wani, MC., Nicholas, AW., Liu, LF., Silber, R., Potmesil, M., DNA topoisomerase I: targeted chemotherapy of human colon cancer in xenografts. *Science*; 246: 1046–48 (1989).
67. Husain, I., Mohler, JL., Seigler, HF., Besterman, JM., Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. *Cancer Res*; 54: 539–46 (1994).
68. Kingsbury, WD., Boehm, JC., Jakas, DR., Holden, HG., Hecht, SM., Gallagher, G., Caranfa, MJ., McCabe, FL., Faucett, LF., Johnson, RK. et al. Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. *J. Med Chem*; 34: 98–107 (1991).
69. Houghton, PJ., Cheshire, PJ., Myers, L., Stewart, CF., Synold, TW., Houghton, JA., Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. *Cancer Chemother Pharmacol*; 31: 229–39 (1992).
70. Friedman, HS., Houghton, PJ., Schold, SC., Keir, S., Bigner, DD., Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. *Cancer Chemother Pharmacol*; 34: 171–74 (1994).
71. Pratesi, G., Tortoreto, M., Corti, C., Giardini, R., Zunino, F., Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts. *Br J Cancer*; 71: 525–28 (1995).
72. Verweij, J., Lund, B., Beijnen, J., de Boer-Dennert, M., Koier, I., Rosing, H., Hansen, H., Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. *Ann Oncol*; 4: 673–78 (1993).
73. Saltz, L., Sirott, M., Young, C., Tong, W., Niedzwiecki, D., Tzy-Jyun, Y., Tao, Y., Trochanowski, B., Wright, P., Barbosa, K., Toomas, F., Kelsen,

- David., Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. *J Natl Cancer Inst*; 85: 1499–507 (1993).
74. Hochster, H., Liebes, L., Speyer, J., Sorich, J., Taubes, B., Oratz, R., Wernz, J., Chachoua, A., Raphael, B., Vinci, RZ., Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. *J Clin Oncol*; 12: 553–59 (1994).
75. Beran, M., Kantarjian, H., Topotecan in the treatment of hematologic malignancies. *Semin Hematol*; 35 (3 suppl 4): 26–31 (1998).
76. Kindler, HL., Kris, MG., Smith, IE., Miller, VA., Grant, SC., Krebs, JB., Ross, GA.Med.C., Slevin, ML., Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer. *Am J Clin Oncol*; 21: 438-41 (1998).
77. Mainwaring, PN., Nicolson, MC., Hickish, T., Penson, R., Joel, Slevin, M., Smith, IE., Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy. *Br J Cancer*; 76:1636–39 (1997).
78. Macdonald, JS., Benedetti, JK., Modiano, M., Alberts, DS., Phase II evaluation of topotecan in patients with advanced colorectal cancer: a Southwest Oncology Group trial (SWOG 9241). *Invest New Drugs*; 15: 357–59 (1997).
79. Creemers, GJ., Wanders, J., Gamucci, T., Vallentin, S., Dirix, L.Y., Schöffski, P., Hudson, I., Verwij, J., Topotecan in colorectal cancer: a phase II study of the EORTC early clinical trials group. *Ann Oncol*; 6: 844–46 (1995).
80. Saltz, LB., Schwartz, GK., Ison, DH., Quan, V., Kelsen, DP., A phase II study of topotecan administered five times daily in patients with advanced gastric cancer. *Am J Clin Oncol*; 20: 621–25 (1997).
81. ten Bokkel Huinink W, Gore M, Carmichael J, Gordon, A., Malfetano, J., Hudson, I., Broom, C., Scarabelli, C., Davison, N., Spaczynski, M., Bolis, G., Malmstrom, H., Coleman, R., Fields, SC., Heron, JF., Topotecan versus



- paclitaxel for the treatment of recurrent epithelial ovarian cancer. *J Clin Oncol*; 15: 2183–93 (1997).
82. Ohe, Y., Sasaki, Y., Shinkai, T., Eguchi, K., Tamura, T., Kojima, A., Kunikane, H., Okamoto, H., Karato, A., Ohmatsu, H., Kanzawa, F., Saijo, N., Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. *J Natl Cancer Inst*; 84: 972–74 (1992).
83. Negoro, S., Fukuoka, M., Masuda, N., Takada, M., Kusunoki, Y., Matsui, K., Takifuji, N., Kudoh, S., Niitani, H., Taguchi, T., Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. *J Natl Cancer Inst*; 83: 1164–68 (1991).
84. Cane, DE., Isoprenoid biosynthesis overview. In DE Cane, ed, *Comprehensive Natural Product Chemistry*, v 2. Elsevier Science Ltd, Amsterdam: 1–13(1999).
85. Sakato, K., Tanaka, H., Mukai, N., Misawa, M., Isolation and identification of camptothecin from cells of *Camptotheca acuminata* suspension cultures. *Agric. Biol. Chem.* 38, 217–218 (1974).
86. Wiedenfeld, H., Furmanowa, M., Roeder, E., Guzewska, J., Gustowski, W., Camptothecin and 10-hydroxycamptothecin in callus and plantlets of *Camptotheca acuminata*. *Plant Cell Tiss. Org. Cult.* 49, 213–218 (1997).
87. Kutchan, T.M., Alkaloid biosynthesis: the basis for metabolic engineering of medicinal plants. *Plant Cell* 7, 1059–1070 (1995).
88. Sheriha, G.M., Rapoport, H., Biosynthesis of *Camptotheca acuminata* alkaloids. *Phytochemistry* 15, 505–508 (1976).
89. Eisenreich, W., Rohdich, F., Bacher, A., Deoxyxylulose phosphate pathway to terpenoids. *Trends Plant Sci.* 6, 78–84 (2001).
90. Yamazaki, Y., Urano, A., Sudo, H., Kitajima, M., Takayama, H., Yamazaki, M., Aimi, N., Saito, K., Metabolite profiling of alkaloids and strictosidine synthase activity in camptothecin producing plants. *Phytochemistry* 62, 461–470 (2003b).
91. Rodríguez-Concepción, M., Boronat, A., Elucidation of the methylerythritol phosphate pathway for isoprenoid biosynthesis in bacteria


- and plastids. A metabolic milestone achieved through genomics. *Plant Physiol*; 130: 1079–1089 (2002).
92. Kuzuyama, T., Seto, H., Diversity of the biosynthesis of isoprene units. *Nat Prod Rep*; 20: 171–183(2003).
93. Eisenreich, W., Rohdich, F., Bacher, A., Deoxyxylulose phosphate pathway to terpenoids. *Trends Plant Sci*; 6: 78–84 (2001).
94. Alberts, AW., Chen, J., Kuron, G., Huff, V., Hoffman, C., Rothrock, J., Lopez, M., Joshua, H., Harris, E., Petchad, A., Monaghan, R., Currie, S., Stapley, E., Albers-Schonberg, G., Hensens, O., Hirshfield, J., Hoogsteen, K., Liesch, J., Springer, J., Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. *Proc Natl Acad Sci USA*; 77: 3957–3961(1980).
95. Kuzuyama, T., Shimizu, T., Takahashi, S., Seto, H., Fosmidomycin, a specific inhibitor of 1-deoxy-d-xylulose 5-phosphate reductoisomerase in the nonmevalonate pathway for terpenoid biosynthesis. *Tetrahedron Lett*; 39: 7913–7916(1998).
96. Javanmardi, J., Stushnoff, C., Locke, E., Vivanco, J.M., Antioxidant activity and total phenolic content of Iranian *Ocimum* accessions. *Food chemistry*; 83: 547-550 (2003).
97. AcKer, S. A. E., and Balen, G. P., Influence of Iron Chelation on the Antioxidant Activity of Flavonoids. *Biochemical Pharmacology*; 56: 935-943 (1998).
98. Maisutisakul, P., Suttajit, M., and Pongsawatmanit, R., Assessment of phenolic content and free radical-scavenging capacity of some Thai indigenous plants. *Food Chemistry*; 100: 1409-1418 (2007).
99. Soobrattee, M.A., Aruoma, D.I., and Bahorun, T., Phenolics as potential antioxidant therapeutic agents: Mechanism and actions. *Mutation Research*; 597:200-213 (2005).
100. Luc, M., Emile, M., Gaydou, and Jean, C., Hubaud. Spectrophotometric measurement of antioxidant properties of flavones and flavonols against superoxide anion. *Analytica Chemica*; 411: 209-216 (2000).

101. Guanghou, S., and Leong, L.P., An improved method for analysis of major antioxidants of *Hibiscus esculentus* Linn. *Journal of Chromatography A*; 1048: 17-24 (2004).
102. Tsimogiannis, D.I., and Oreopoulou, V., Free radical scavenging and antioxidant activity of 5,7,3',4'-hydroxy-substituted flavonoids. *Innovative Food Science and Emerging Technologies*; 5:523-528 (2004).
103. Mariken, J.T.J. Arts., Dallinga, JS., Hans-Peter, V., Guido, R.M.M. H., Aalt, B., A Critical appraisal of the use of the antioxidant capacity (TEAC) assay in defining optimal antioxidant structures. *Food Chemistry*; 80: 409-414 (2003).
104. Guido, R.M.M. H., Mariken J.T.J. A., Bast, A., Michael, D.C., Structure and activity in assessing antioxidant activity in vitro and in vivo "A critical appraisal illustrated with the flavonoids" *Environmental Toxicology and Pharmacology*; 21: 191-198 (2006).
105. Pier-Giorgio, P., Flavonoids as Antioxidants. *Journal of Natural Products*; 63: 1035-1042 (2000).
106. Hollman, P.C.H., and Katan, M.B., Dietary Flavonoids: Intake, Health Effects and Bioavailability. *Food and Chemical Toxicology*; 37: 937-942 (1999).
107. Julia, P. MS., Johanna, D. DSc.J., RD., Flavonoids: Dietary Occurrence and Biochemical Activity. *Nutrition Research*; 18: 1995-2018 (1998).
108. Donald, A., Free radical and Antioxidant protocols, Methods in molecular biology, 186. Humana Press Inc. Totowa, New Jersey, USA. (1998).
109. Marcel, R., and Pedro, B.C., Free radicals and oxidation phenomena in biological system. Marcel Dekker Inc. New York, USA. (1994).
110. Noguchi, N., and Niki, E., Chemistry of Active Oxygen Species and Antioxidants, Antioxidant Status, Diet, Nutrition, and Health. Research Center for Advanced Science and Technology, University of Tokyo, Japan. (1998).

111. Bondet, V., Brand-Williams, W., Berset, C., Kinetics and Mechanisms of Antioxidant Activity using the DPPH• Free Radical Method. *Lebensm.-Wiss. u.-Technol*; 30: 609–615 (1997).
112. Brand-Williams, W., Cuvelier, M. E., Berset, C., Use of a Free Radical Method to Evaluate Antioxidant Activity. *Lebensm.-Wiss. u.-Technol*; 28: 25-30 (1995).
113. Dax, S.L., Antibacterial Chemotherapeutic Agents. Research Institute Spring House Pennsylvania, USA. (1997).
114. Rang H.P. et. al. Fifth Edition Pharmacology. CHURCHILL LIVINGSTONE, An imprint of Elsevier Science Limited, UK. (2003).
115. Zaika, LL., Species and herbs: their antimicrobial activity and its determination. *J.Food safety*; 9: 97-118 (1975).
116. Gordon, MC., David, JN., Natural product drug discovery in the next millennium. *Pharm Biol*; 139: 8-17 (2001).
117. Crodell, GA., Pharmacognosy: New roots for an old science. In: Attar-Rahman, Basha FZ, editors. Studies in natural products chemistry. v 13: Bioactive natural products (Part A). Elsevier; (1993).
118. Mojab, F., Kamalinejad, M., Ghaderi, N., Vahidipour, H.R., Phytochemical Screening of Some Species of Iranian Plants. *J. IJPR*; 2: 77-82 (2003).
119. Wagner, H., Bladt, S., Zgainski, E.M., *Plant Drug Analysis*. Springer-Verlag, Berlin Heidelberg–NewYork-Tokyo; 1984.
120. Yosprasit, K., The Delvelopment of Topical Antibacterial Formulation from Extract of Punica granatum Rind. M. Sc. (Pharmaceutical Technology) thesis. Chiang Mai University; 104-106: (2003).
121. Blois, M.S., Antioxidant determinations by the use of a stable free radical. *Nature*; 181: 199-1200: (1958).
122. Irobi, ON., Moo-Young, M., Anderson, WA., Daramola, SO., Antimicrobial activity of the bark of Bridelia ferruginea (Euphorbiaceae). *Intern. J. Pharmacog*; 34: 87-90(1994).
123. Skehan, P., Storeng, R., Seudiero, D., Monks, A., McMahan, J., Vistica, D., Warren, J. T., Bokesch, H., Kenny, S., Boyd, M. R. New

- colorimetric cytotoxic assay for anticancer drug screening. *J. National Cancer Institute*; 82: 1107–1112 (1990).
124. Brien, J.O., Wilson, I., Orton, T., Pognan, F. Investigation of the alamar blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. *Eur. J.Biochem*; 267: 5421-5426(2000).
125. Ragasa, C.Y., Tepora, M.M., Ridieout, J.A. Terpenoids from *Tithonia diversifolia*. *Journal of Research in Science, Computing, and Engineering*; 4(1): 1-7 (2007).
126. Lee, S., Kim, B-K., Cho S.H., Shin, K.H. Phytochemical Constituents from the Fruits of *Acanthopanax sessiliflorus*. *Arch Pharm Res*; 25(3): 280-284 (2002).
127. Moghaddam, F.M., Farimani, M.M., Salahvarizi, S., Amin, G. Chemical Constituents of Dichloromethane Extract of Cultivated *Satureja Khuzistanica*. *eCAM*; 4(1): 95-98 (2007).
128. Liu, X., Tian, F., Zang, H-B., Pilarinou, E., Mclaughlin, J.L. Biologically active Blumenol A from the leaves of ANNONA GLABRA. *Natural Product Letters*; 14(1): 77-81(1999).
129. Aassila, H., Bourguet-Kondracki, M.L., Rifai, S., Fassouane, A., Guyot, M. Identification of Harman as the Antibiotic Compound Produced by a Tunicate-Associated Bacterium. *Mar.Biotechnology*; 5: 163-166 (2003).
130. Seki, H., Tokunaga, T., Utsumi, H., Yamaguchi, K. Determination of Heteronuclear Long-Rang  $^1\text{H}$ -  $^{13}\text{C}$  and  $^1\text{H}$ -  $^{15}\text{N}$  Coupling Constants of Harman by Modified *J*-HMBC 2D NMR Techniques. *Tetrahedron*; 5: 2935-2939 (2000).
131. Kongduang, D., Wungsintaweekul, J., De-Eknamkul, W. Biosynthesis of  $\beta$ -sitosterol and stigmasterol proceeds exclusively via the mevalonate pathway in cell suspension cultures of *Croton stellatopilosus*. *Tetrahedron Letters*; 49: 4067-4072 (2008).
132. Moghaddam, FM., Farimani, MM., Salahvarzi, S., Amin, G. Chemical constituents of Dichloromethane extract of Cultivated *Satureja khuzistanica*. *eCAM*; 4(1): 95-98 (2007).

133. Begum, T., Rahman, MS., Rashid, MA. Phytochemical and Biological Investigations of *Phyllanthus reticulatus*. *Dhaka Univ.J. Sci.*5(1): 21-23 (2006).
134. Siddiqui, BS., Sattar, FA., Ahmad, F., Begum, S. Isolation and Structural Elucidation of Chemical Constituents from the Fruits of *Morinda citrifolia* Linn. *Arch Pharm Res.* 30(8): 919-923 (2007).



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่  
Copyright© by Chiang Mai University  
All rights reserved